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Summary
Background: Low molecular weight proteins (LMWP) are considered uremic toxins. There is controversy
whether in peritoneal dialysis (PD) the elimination of these toxins is influenced mainly by dial-
ysis or by residual renal function (RRF).
Material/Methods: The aim of our study was to evaluate the relationship between serum levels of selected
LMWPs, dialysis adequacy, and RRF in PD patients. 27 stable subjects were studied, mean age
50±11, dialyzed for a median period of 10 months. Serum activity of acid RNA-se and alka-
line RNA-se was measured by spectrophotometry, and serum alpha1-microglobulin (α1M) con-
centration by ELISA. Kt/V and weekly creatinine clearance (wClCr) were assessed as adequacy
indices (both as the sum of renal and dialysis components) and RRF as the mean of residual
urea and creatinine clearances.
Results: Significant inverse correlations were found between RRF and α1M level, as well as alkaline
RNA-se activity (p<0.0001). A similar relationship was found for residual Kt/V (p<0.0001 for
α1M and alkaline RNA-se). There was no significant correlation between acid RNA-se activity
and any tested parameter of adequacy. When the cutoff points of wClCr = 60 L/week/m
2, total
Kt/V = 2.0, or RRF=2.0 ml/min were used, we found α1M level and alkaline RNA-se activity
to be significantly lower in patients with higher values of the respective parameters.
Conclusions: RRF plays an important role in elimination of LMWP in PD. The activity of alkaline RNA-se
and acid RNA-se behaves differently in these patients.
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BACKGROUND
Uremic toxemia occurs due to the effect of catabolite accu-
mulation, which adversely affects the function of various
organs and tissues. These substances may be divided into
several categories. According to their molecular weights,
they are classified as low (<300), middle (300–15,000) and
high molecular weight uremic toxins (>15000) [1,2]. The
urea and creatinine concentrations or urea and creatinine
elimination rates (clearances) are generally used as a com-
mon denominators of uremic toxin accumulation. The
same indices are used to assess dialysis adequacy. Though
a great amount of data has demonstrated a relationship
between the patients’ clinical outcome, normalized clear-
ance of urea (Kt/V), and weekly creatinine clearance (ClCr)
[3–6], the importance for the development of toxemia of
many individual compounds accumulating in the plasma
of end-stage renal disease patients is still unknown. Thus
particular interest has been focused on the group of low
molecular weight proteins (LMWPs) accumulating in plas-
ma, along with gradual loss of renal function, remaining
extremely elevated in patients maintained on renal
replacement therapy [7–11]. As shown by Jung et al., the
accumulative increase of plasma ribonuclease is a more
sensitive indicator of renal function impairment than crea-
tinine [12]. A decrease in glomerular filtration is the most
common cause of elevated plasma α1 microglobulin (α1M).
Others authors suggest that the measurement of α1M may
be helpful in the so-called creatinine-blind range of
glomerular filtration rate (GFR) decrease. α1M is probably
superior to β2-microglobulin or retinol-binding protein to
measure loss of renal function, although probably cystatin
C elimination measurement would be best for this pur-
pose [13]. The elimination of α1M with urine also appears
to be a useful diagnostic tool of subclinical nephropathy,
as a marker of early renal damage, for example in patients
with stable angina without symptoms of kidney disease
[14]. On the other hand, serum β2-microglobulin concen-
tration is related not only to the current level of renal
function, but also to many pathologies associated with
inflammatory process or cellular damage, since this pro-
tein is one of the domains of histocompatibility class I
HLA antigens [15,16].
The LMWP accumulation process may serve as a model
of uremic toxin accumulation independently of the urea
and creatinine removal rate. Urea and creatinine elimi-
nation are assessed in the evaluation of dialysis adequa-
cy because of the simplicity, but the serum levels of
these solutes do not reflect the state of toxemia, as they
are not toxic themselves. It would be much more appro-
priate to assess other compounds of larger molecular
weight, but such methods have not been developed as
routine procedures for everyday clinical practice.
The aim of our study was to make a cross-sectional mea-
surement of serum levels of selected LMWPs in patients
on continuous ambulatory peritoneal dialysis (CAPD), and
to evaluate the potential impact of residual renal function
and dialysis adequacy on serum levels of these proteins.
The most important issue in this study was to assess the
contribution and importance of both residual diuresis and
peritoneal dialysis to the elimination of LMWPs.
MATERIAL AND METHODS
27 clinically stable CAPD patients were enrolled into the
study: 13 females, 14 males, ranging in age from 22 to
74 years (mean 50±11 years) dialyzed for a median peri-
od of 10 months (range 1–56 months). The etiology of
end–stage renal disease included primary glomerulopa-
thy in 13 patients, polycystic kidney disease in 2, chronic
pyelonephritis in 1 and amyloidosis in 1. In 10 cases no
primary diagnosis of chronic nephropathy had been
established, mainly due to late referral to the renal unit.
Samples for RNA-ses were centrifuged at 1000 g, 4°C.
RNA-se activity was determined from 20-µl serum sam-
ples incubated with 180 µl of 100 mmol/l sodium phos-
phate buffer (8.5 ml of 0.2 M. NaH2PO4 plus 91.5 ml of
0.2 M. Na2HPO4 – pH 7.8 for alkaline RNA-se or 68.5
ml of 0.2 M. NaH2PO4 plus 31.5 ml of 0.2 M. Na2HPO4
– pH 6.5 for acid RNA-se), plus 200 µl of RNA substrate
(6 g/l RNA in sodium phosphate buffer, pH 7.8 for alka-
line RNA-se or pH 6.5 for acid RNA-se). After 60 min-
utes of incubation the RNA precipitating agent (600 µl
of 6 mmol/l uranyl acetate) was added. The samples
were centrifuged at 4°C. 100 µl of clear supernatant was
taken off and diluted in 1.4 ml of distilled water. Then
spectrometric absorption at 260 nm was determined. A
blank assay was prepared exactly as the samples, omit-
ting the incubation step. Each test was performed in
duplicate, and final RNA-se activity was calculated as a
mean value.
All values were expressed in arbitrary units. One unit of
RNA-se activity was the amount of hydrolized RNA
which under standard conditions liberates low molecu-
lar RNA-degradation products (A260=0.360×cm
–1). RNA-
se activity was calculated by equation (1):
RNA-se (U/l) = [(A260–0.02)/0.316]
2 (1)
This equation shows the relationship between RNA-se
concentration and the increased light absorption at 260
nm.
Acid and alkaline RNA-se isoenzymes were assayed by
determining the total RNA-se activity at pH 6.5 (RNA-
se6.5) and pH 7.8 (RNA-se7.8), and then further calcula-
tions were performed using equations (2) and (3):
alkaline RNA-se = 1.11 × RNA-se7.8–0.67 × RNA-se6.5 (2)
acid RNA-se = RNA-se6.5–0.17 × alkaline RNA-se (3)
The origin of all three equations used here has been
described in detail elsewhere [10,17].
α1M was determined in serum using the nephelometric
method (Behring Nephelometer, Behringwerke AG,
Marburg, Germany). Intra-assay variability for this assay
was less than 5%.
Dialysis adequacy was assessed using the sum of dialysis
and residual urea and creatinine clearances, standardized
to distribution volume (Kt/V) or body surface area
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(wClCr). Serum, urine and dialysate urea and creatinine
levels were measured using a Hitachi 917 analyzer. Urine
and dialysate urea and creatinine were measured in 24-
hour collections. Fasting blood was taken in the morning
the day after collection was completed. Adequacy indices
(Kt/V, wClCr) were calculated using the licensed, commer-
cially available software package Nephron for Windows
(DDPS, Cracow, Poland). This program utilizes anthro-
pometric Watson formulas for distribution volume calcu-
lations. RRF was expressed as the mean of the sum of
residual renal urea and creatinine clearances. In addi-
tion, the dialysate-to-plasma creatinine (D/PCreat.) ratio in
the standardized Peritoneal Equilibration Test (PET) was
calculated for every subject, according to the method
described by Twardowski [18].
Statistical analysis
Statistical analysis of the data was performed with
Statistica 5.1 software (StatSoft Inc, Tulsa, Oklahoma,
USA). Shapiro-Wilk’s W-test of normality was used for
data distribution analysis. All variables with normal dis-
tribution were presented as mean ±SD; those with non-
normal distribution, as median and range. The t-Stu-
dent test for inter-group comparisons and Pearson test
for correlations between variables were used for nor-
mally distributed data, whereas the U Mann-Whitney
and R Spearman test, respectively, were applied to non-
normally distributed data. We considered a p value less
than 0.05 to be statistically significant.
RESULTS
The parameters analyzed in the present study are summa-
rized in Table 1. The median value of D/PCreat. was 0.56
(range 0.35–0.8), with 14 patients classified as Low/Low-
Average Transporters (L/LA, median 0.51; range
0.35–0.56), and the remaining 13 as High/High-Average
Transporters (H/HA, median 0.76; range 0.68–0.8).
Significant negative correlations were demonstrated for
RRF and the α1M level, as well as RRF and alkaline
RNA-se serum activity (R=–0.83; p<0.0001 and
R=–0.73; p<0.0001, respectively; R Spearman rank
test). A similar relationship was found for residual Kt/V
(R=–0.48; p<0.0001 for α1M and r=–0.79; p<0.0001
for alkaline RNA-se). Inverse relationships were also
found for the level/activity of both mentioned proteins
and residual diuresis volume (R=–0.76; p<0.0001 for
α1M and R=–0.69; p<0.0001 for alkaline RNA-se), as
shown in Table 2.
The total values of both wClCr and Kt/V depended
strongly on residual components of these adequacy
parameters (r=0.88; p<0.0001 for total and residual
wClCr, and r=0.64; p<0.005 for total and residual
Kt/V), whereas no relationship was observed between
total and dialytic components.
No statistically significant correlation was found between
acid RNA-se activity and any tested parameter of ade-
quacy. It is worth nothing that there were positive corre-
lations between α1M, alkaline RNA-se and dialytic com-
ponents of both analyzed adequacy parameters. α1M
serum level and alkaline RNA-se but not acid RNA-se
activity were proportional to dialysis treatment duration
(Table 2).
Dividing our patients according to the cutoff values of a
total wClCr of 60 L/week/m
2, total Kt/V of 2.0 or RRF of
2.0 ml/min, we found α1M serum level and alkaline
RNA-se activity to be significantly lower in patients with
values above the respective cutoff lines (Table 3). No dif-
ferences were found in serum concentration or activity
of tested LMWPs between L/LA vs. H/HA transporters.
DISCUSSION
The molecular weight of serum RNA-ses fits in the
range between 8,500 and 33,000, whereas the molecular
weight of α1M is equal to 30,000. In comparison, β2-
microglobulin, the protein usually used to assess the
accumulation of larger molecular size toxins, has a mol-
ecular weight of 11,800. Thus the analyzed proteins
should be classified into the group of toxins with the
largest molecular size [1].
The results obtained in this study indicate that serum
concentrations of the selected low molecular weight pro-
teins directly depend upon residual diuresis. Both α1M
level and alkaline RNA-se activity correlated inversely
with the values of total and residual components of both
tested indices of adequacy (residual Kt/V and wClCr).
Differences in elimination of substances with higher
molecular weight in dialyzed patients with preserved
residual diuresis in comparison to anuric individuals
have already been demonstrated for β2-microglobulin
[19,20]. Not only β2-microglobulin, but also RNA-se
seem to be good markers of decreasing glomerular fil-
tration rate [12,21]. It has been suggested that RNA-se
may be a very useful and sensitive indicator of
decreased renal function in patients who still maintain
normal creatinine clearance [12].
Interestingly, serum levels of α1M and alkaline RNA-se
correlated directly with the dialytic components of both
analyzed adequacy indices. This phenomenon may be
Abbreviations: as in the text
Unit SD/RangeMean/Median
α1M
Acid RNA-se
Alk. RNA-se
wClCr total
wClCr dial.
ClCr res
Kt/V total
Kt/V dial.
Kt/V res.
RRF
mg/l
U/l 
U/l
l/week/1.73m2
l/week/1.73m2
ml/min
–
–
–
ml/min
29.4
0.29
1.56
69.5
37.6
2.81
1.96
1.4
0.63
2.29
14.8
0.038–0.78
0.42
40.0–127.1
9.9
0–9.24
0.35
0.39
0–1.7
0–7.07
Table 1. The mean/median values and SD/range of the serum
levels/activity of the tested low molecular-weight proteins,
and dialysis adequacy parameters.
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explained by the well-known fact that the dialysis dose
increases following RRF decline, as do the dialytic com-
ponents of Kt/V or wClCr. Our findings may suggest that
an increased dialysis dose cannot replace residual renal
function in terms of LMWP removal.
As shown in our study, acid RNA-se behaves in a differ-
ent mode compared to alkaline RNA-se. This may be
explained by the differing origin of these two enzymes.
Acid RNA-se is mainly derived from leukocytes, and its
release during dialysis may reflect bioincompatibility of
renal replacement therapy, as has been shown for
hemodialysis (HD) [22,23]. It has been demonstrated
that a HD session leads to increased activity of different
enzymes, including acid RNA-se, mainly due to leuko-
cyte degranulation on dialysis membranes [11,24]. On
the other hand, alkaline RNA-se is predominantly a
pancreatic enzyme, and its release is probably less influ-
enced by dialysis itself, hence the effect of its removal
may be demonstrated. CAPD is a continuous mode of
dialysis with relatively steady-state levels of various
solutes. However, the continuous stimulation of leuko-
cytes by bioincompatible dialysis fluid resulting in the
prolonged release of leukocyte enzymes (with a rate
comparable to their elimination) may be taken under
consideration.
Many data indicate that residual renal function is impor-
tant for obtaining the desired values of dialysis adequacy
indices, and its impact on the clinical outcome of renal
replacement therapy is well documented [25–27].
Contemporary methods of dialysis allow replacement of
reduced kidney function. It is beyond doubt that an
increasing dialysis dose allows for efficient elimination of
small solutes to an extent compensating for deteriorating
renal function. It seems, however, that this treatment
cannot compensate for lost renal elimination of sub-
stances with higher molecular weights, responsible for
the development of uremic toxemia. This is due to the
lack of the fundamental metabolic function of the kid-
neys in the elimination of these substances, which also
includes protein catabolism. In this respect, the question
as to whether deteriorating renal function can be
replaced with increasing dialysis dose remains open.
Based on the results of the latest large-scale prospective
studies, which failed to demonstrate any substantial
impact of small solute clearance on long-term survival,
we believe that the assessment of the serum concentra-
tion of substances with larger molecular weight appears
to be more appropriate to describe uremic toxemia [28].
CONCLUSIONS
The results of our study seem to indicate that serum lev-
els or enzymatic activity of the selected small-molecule
proteins depend on residual renal function. This means
that the assessment of peritoneal dialysis efficacy by ref-
erence to the elimination of these substances alone, par-
ticularly among patients without residual renal function,
does not reflect the actual accumulation of toxic metabo-
lites. It should be noted that the behavior of acid and
alkaline RNA-se activity is different, with no relationship
between acid RNA-se and RRF or dialysis adequacy.
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